Fsd Pharma (TSE:HUGE) has released an update.
FSD Pharma Inc. has partnered with iNGENu CRO to conduct a Phase 1 clinical study on Lucid-21-302, a novel neuroprotective compound aimed at treating multiple sclerosis. The study follows a successful single ascending dose trial and will evaluate the safety and pharmacokinetics of multiple doses in healthy adults. Lucid-21-302 has demonstrated potential in preclinical models to prevent demyelination, a key factor in the progression of neurodegenerative diseases.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
